Cats, Cannabinoids, and Regulatory Confusion

Cannabinoid use in cats remains controversial largely because of inconsistent regulations rather than safety concerns. Many veterinarians are reluctant to recommend or discuss cannabidiol (CBD) products due to fears of legal or professional repercussions, despite growing research supporting their safety and potential therapeutic benefits. Compared to some commonly prescribed pain and anxiety medications, CBD appears to have relatively mild and manageable side effects. Traditional treatments, including NSAIDs, opioids, gabapentin, trazodone, and dexmedetomidine, can present significant risks, particularly with long-term use.

Research has explored CBD for feline pain, anxiety, and long-term safety, with encouraging results. Advocates argue that veterinarians should be able to provide guidance on CBD products rather than leaving pet owners to rely on social media, retail employees, or cannabis dispensary staff. Product quality remains important, and reputable manufacturers provide certificates of analysis (COAs) that verify cannabinoid content, potency, and product consistency.